Market Research Report — October 7, 2026

Let me analyze this task carefully. I'm updating an evolving research report based on new findings. The original question asks for:

1. Market structure, general trends, and evidence-backed bullish and bearish theses
2. A list of best stock performers and worst performers
3. Bullish and bearish sector outlooks
4. Use fresh news

I have the current report and 10 new findings. I need to integrate the new findings, remove redundancy, resolve contradictions, and maintain logical flow.

Let me go through each finding and identify what new information it provides:

Finding 1 — Stockanalysis.com top gainers past month

• Large-cap growth/tech led (Nasdaq 100 +6.04%, S&P 500 +1.96%), value/small-caps lagged (Dow -2.11%, Russell 2000 -4.13%)
• Best performers: micro-cap high-vol biotech/pharma (SVRN, PDSB, AEMD, APUS, INDP), fintech/digital assets (SDEV, AVAT, CD), AI/advanced materials (MEDS, FEAM), gains ~104% to ~382%
• Worst performers not itemized
• This is largely already in the report

Finding 2 — Quant500 S&P 500 gainers/losers Oct 6, 2026

• S&P 500 advanced, 339 of 501 up, median +0.47%, SPY +0.55%
• Biggest gainer: Ciena (CIEN, +13.85%), biggest loser: Seagate (STX, -9.18%)
• Top gainers: Utilities (Constellation Energy, Vistra, NRG Energy), Technology (Ciena, Corning, Marvell), Basic Materials (Corteva)
• Top losers: Technology (Seagate, Western Digital, KLA, Lam Research), Healthcare (Moderna, DexCom, Thermo Fisher)
• Utilities led (+1.87%, all 31 up), Consumer Cyclical (+1.15%), Consumer Defensive (+0.88%), Healthcare weakest (-0.45%, 38 of 59 down), Communication Services -0.12%
• This is largely already in the report

Finding 3 — Business Insider market movers

• Top gainers: NRG Energy (+7.02%), Comfort Systems USA (+6.12%), Corning (+6.02%)
• Energy, industrial/electrical services, semiconductors (Marvell), cruise lines (Royal Caribbean, Norwegian Cruise Line)
• Worst: Seagate (-9.18%), Moderna (-7.75%), Western Digital (-6.93%)
• Semiconductors (KLA, Lam Research, Teradyne, Intel), biotech/pharma (Moderna, Illumina, DexCom, Thermo Fisher), logistics (C.H. Robinson)
• New: Comfort Systems USA, Teradyne, C.H. Robinson, Norwegian Cruise Line

Finding 4 — Altindex bottom performers week

• Worst 7-day: Glimpse Group (VRAR) -86.5%, Corteva (CTVA) -82.1%, Direct Digital (DRCT) -64.5%, CommScope (COMM) -59.6%, Steakholder Foods (STKH) -58.6%
• This is already in the report

Finding 5 — Yahoo Finance S&P 500 history

• Only historical price data, no performers
• S&P 500 closed 7,818.93 on Oct 6 (+0.58%), near multi-month highs
• Trailing year: from ~6,830-6,900 late Dec 2025 to over 7,800, dip to ~6,475 early April 2026
• No performers, outlooks, or news
• New: S&P 500 level data

Finding 6 — FRED

• Defines market structure, three indices, links to VIX, 10yr yields, dollar index, Fed funds
• No actual performers, outlooks, or news
• Not useful for content

Finding 7 — StockCharts.com

• No actual data, just describes galleries
• Not useful

Finding 8 — Investors.com

• Major indexes at record highs led by rate hopes and soft jobs report
• Small caps paused, one sector took "bloody nose"
• Best: AI/hardware (AMD, TSMC on 'terafab' capacity chatter), Tesla (486,532 EVs Q3, beating estimates), Nvidia, Micron, Meta
• Bullish: AI hardware demand, strong EV deliveries
• Bearish: underperforming sector, weakening gas vehicle sales below 50%
• New: soft jobs report, rate hopes, Tesla EV deliveries, TSMC terafab, "bloody nose" sector

Finding 9 — Dowjonestoday.net

• Market structure: Dow price-weighted, S&P value-weighted, Nasdaq tech-concentrated
• Trend/risk through Oct 6: Nasdaq leading (YTD +18.75%, 10yr +420.08%), highest volatility (18.68%), drawdown -36.40%; S&P 500 middle (YTD +14.22%, vol 12.99%); Dow lags (YTD +7.19%), steadier (vol 12.77%, drawdown -37.09%)
• New: detailed YTD returns and volatility/drawdown data

Finding 10 — tradewithmaya.com

• Large-cap tech concentration, NVDA largest holding
• Best: VST (+10.78%), MRVL (+5.81%), ZS (+5.18%)
• Worst: MRNA (-7.76%), TWLO (-6.82%), INTC (-3.18%)
• Bullish: AAPL, MSFT drive returns, tech indices benefit from AI/semi strength (AVGO, MRVL, CSCO)
• Bearish: concentration risk in NVDA, volatility in MRNA, TWLO
• New: VST, ZS, TWLO, AVGO, CSCO

Now let me think about contradictions and how to resolve them:

1. YTD returns: The report currently cites Russell 2000 +14.72%, U.S.A. 500 +14.12%, Dow +7.03%. Finding 9 gives Nasdaq +18.75%, S&P 500 +14.22%, Dow +7.19%. These are consistent (Dow ~7%, S&P ~14%). Finding 10 mentions NVDA largest holding. No real contradiction, just additional data.

2. The report mentions "U.S.A. 500" — this is likely the Invesco S&P 500 Equal Weight or a different index. Actually "U.S.A. 500" might be a typo or a specific ETF. Let me keep it as is since it's from Finding 1 in the original.

Wait, actually the original report's Finding 1 was about YTD gains with Russell 2000 +14.72% and U.S.A. 500 +14.12%. The new Finding 1 is different (past month). So there are two different "Finding 1"s — the original report's findings and the new findings. I need to be careful. The new findings are labeled Finding 1 through Finding 10 in the "New findings" section. I should use these new finding numbers for the new citations.

Let me reconcile the YTD data:

• Original report Finding 1 (old): Russell 2000 +14.72%, U.S.A. 500 +14.12%, Dow +7.03%
• New Finding 9: Nasdaq +18.75%, S&P 500 +14.22%, Dow +7.19%
• New Finding 10: NVDA largest holding

These are all consistent. I can add the Nasdaq and S&P 500 YTD data from Finding 9.

1. Best/worst performers — the report already has comprehensive lists. New findings add:

• Finding 3: Comfort Systems USA, Teradyne, C.H. Robinson, Norwegian Cruise Line
• Finding 8: AMD, TSMC, Tesla, Nvidia, Micron, Meta
• Finding 10: VST, ZS, TWLO, AVGO, CSCO

Let me now think about the structure of the updated report. I'll keep the general structure but enhance it with new data.

Let me draft the updated report:

Market Structure & General Trends

Broad YTD gains with a recent style rotation. U.S. equities posted broad year-to-date gains. On a YTD basis, the Nasdaq 100 led (+18.75%), the S&P 500 advanced +14.22%, and the Russell 2000 (+14.72%) and S&P 500 equal-weight peers (+14.12%) outperformed the Dow (+7.03–7.19%) [Finding 1] [Finding 9]. That leadership has since shifted—over the past month, large-cap growth/tech reclaimed the lead (Nasdaq 100 +6.04%, S&P 500 +1.96%) while value and small-caps fell behind (Dow −2.11%, Russell 2000 −4.13%) [Finding 1]. The net picture is a market with strong YTD breadth that has recently rotated back toward mega-cap tech/growth.

Hmm, let me be careful with the "U.S.A. 500" reference. Actually, I think I should keep the original data but integrate. Let me reconsider.

Actually, the original report's YTD data (Russell 2000 +14.72%, U.S.A. 500 +14.12%, Dow +7.03%) came from the original Finding 1. The new Finding 9 gives Nasdaq +18.75%, S&P 500 +14.22%, Dow +7.19%. I can combine these.

Let me think about volatility/drawdown data from Finding 9:

• Nasdaq: YTD +18.75%, 10yr +420.08%, volatility 18.68%, drawdown -36.40%
• S&P 500: YTD +14.22%, volatility 12.99%
• Dow: YTD +7.19%, volatility 12.77%, drawdown -37.09%

This is good evidence for the "concentration drives returns at cost of volatility" thesis.

Extreme concentration at the top. Market capitalization remains highly concentrated: the five largest names—NVDA ($5.8T), AAPL ($4.9T), GOOGL ($4.2T), MSFT ($3.9T), and AMZN (~$2.7T)—anchor the major indices [Finding 2]. NVIDIA is the single largest holding across the NASDAQ 100, S&P 500, and Russell 2000 [Finding 10]. This concentration underpins a momentum-driven, concentration-heavy bull case tempered by extreme dispersion in the long tail [Finding 1].

Momentum dispersion. Relative-strength and Sharpe data confirm leaders carry strong momentum z-scores (e.g., ERAS +5.16, MU +5.16) versus deeply negative readings on decliners, reinforcing a momentum-driven tape [Finding 1].

Index risk profile. Tech concentration drives the Nasdaq's higher long-run returns at the cost of higher volatility (18.68%) and deeper drawdowns (−36.40%), while the Dow's blue-chip tilt makes it steadier (volatility 12.77%) but slower [Finding 9].

Macro backdrop. Index highs are being driven by rate hopes and a soft jobs report; small caps paused, and one unnamed sector took a "bloody nose" [Finding 8].

Methodological caveat: sources update at differing cadences and apply different filters (e.g., liquidity floors, split-adjustment), so figures should be read with their stated dates in mind [Finding 2].

Best & Worst Performers

Year-to-Date

• Top gainers are dominated by semiconductors/tech: MU (+231.48%), alongside DD, MRVL, LITE, AMD, and INTC [Finding 1]. Micro-cap/speculative names show extreme YTD gains as well—MGRT (Mega Fortune, +1400.0% YTD / +2149.9% 52W) and ANL (Adlai Nortye, +947.8% YTD / +735.8% 52W), with biotech names MRNA, Twist, and Iovance prominent [Finding 2].
• Top decliners are nearly all micro-cap/biotech names near −99% to −100% (ADTX, HUBC, LIVG, TMGI, LNKS) [Finding 1]. Within the S&P 500, the biggest decliners are CTVA (−79.49%), CSGP, FICO, LULU, and BSX (−55% to −79%); within the Tech 100, APP, INTU, ALNY, MNST, and CRWD [Finding 1].

Past 30 Days

• Top gainers are dominated by small-cap biotech and speculative names: Nuburu (+2900%), NovaBay Pharmaceuticals (+2066.7%), and VerifyMe (+1396.7%) [Finding 5]. Broader lists show micro-cap biotech/pharma (SVRN, PDSB, AEMD, APUS, INDP), fintech/digital assets (SDEV, AVAT, CD), and AI/advanced materials (MEDS, FEAM) with gains of ~104% to ~382% [Finding 7].
• Top losers (7-day window, to filter single-session noise): Glimpse Group (VRAR, ~−86.5%), Corteva Agriscience (CTVA, −82.1%), Direct Digital Holdings (DRCT, −64.5%), CommScope (COMM, −59.6%), and Steakholder Foods (STKH, −58.6%) [Finding 10].

Single-Session Movers (October 6, 2026)

• S&P 500 gainers: Ciena (CIEN, +13.85%) led, alongside Constellation Energy, Vistra, Corning, and Marvell [Finding 8] [Finding 9].
• S&P 500 losers: Seagate Technology (STX, −9.18%) led the decliners, followed by Moderna (−7.75%) and Western Digital (−6.93%) [Finding 8] [Finding 9].
• Cross-market daily movers: MTEN (+83%) and BIYA (+71%) led gainers; VCIG (−27%) and XHG (−21%) led decliners [Finding 2].

Hmm, I need to add the new single-session movers from Findings 3 and 10. Let me integrate:

• Finding 3: NRG Energy (+7.02%), Comfort Systems USA (+6.12%), Corning (+6.02%); decliners: KLA, Lam Research, Teradyne, Intel, C.H. Robinson
• Finding 10: VST (+10.78%), MRVL (+5.81%), ZS (+5.18%); MRNA (-7.76%), TWLO (-6.82%), INTC (-3.18%)

Let me reorganize the single-session section to be cleaner.

Bullish & Bearish Sector Outlooks

Bullish

• Semiconductors / AI hardware. Sustained momentum-factor leadership—MU, MRVL, LITE, AMD, INTC on a YTD basis, with Marvell and Corning among daily gainers [Finding 1] [Finding 8] [Finding 9]. AMD and TSMC broke out on "terafab" capacity chatter; Nvidia, Micron, and Meta also in focus [Finding 8].
• Utilities & power. Constellation Energy, Vistra, NRG Energy, and Public Service Enterprise led daily gainers; Utilities was the strongest sector on Oct 6 (+1.87%, all 31 stocks up) [Finding 6] [Finding 8].
• Energy. Prominent among gainers alongside utilities [Finding 6] [Finding 8].
• Consumer cyclical & defensive. Both advanced on Oct 6 (+1.15% and +0.88% respectively), with cruise lines (Royal Caribbean, Norwegian Cruise Line, Carnival) and consumer names appearing [Finding 8] [Finding 9].
• Short-covering signals. Short-interest decreases (bullish) led by MUA (−92.88%) and AVAT (−86.93%) [Finding 2].

Bearish

• Healthcare / biotech (large-cap). Weakest sector on Oct 6 (−0.45%, 38 of 59 down); Moderna, DexCom, Thermo Fisher, and Illumina among decliners [Finding 8] [Finding 9].
• Storage / legacy tech. Seagate, Western Digital, KLA, and Lam Research faced selling pressure [Finding 8] [Finding 9].
• Small-cap / value (recent). Russell 2000 −4.13% over the past month signals broad small-cap weakness [Finding 7].
• Short-covering signals. Short-interest increases (bearish) led by TEVA (>999.99%) [Finding 2].
• Extreme long-tail dispersion. Near-total losses in micro-cap/biotech names (−99% to −100%) underscore tail risk [Finding 1].

Fresh News (Oct 6–7, 2026)

• Corteva (CTVA) was the biggest single news loser (−83.8%) [Finding 2], with ~−82% declines over the past week [Finding 10]—yet it rebounded +12.27% on Oct 7 to lead the S&P 500 gainers [Finding 6], a high-volatility reversal.
• Heartbeam (BEAT) was the biggest news gainer (+50.5%) [Finding 2].
• Income focus: UWMC led dividend yield at 33.33% [Finding 2].
• Tesla rose after delivering 486,532 EVs in Q3, beating estimates; gas vehicle sales dipped below 50% for the first time [Finding 8].

Now let me reconsider the citations. I need to be careful about which finding number refers to which source. The new findings are Finding 1-10. But the original report already used Finding 1-10 for its own sources. This is a conflict.

Wait, let me re-read the task. The "New findings from this round" section lists Finding 1 through Finding 10. These are NEW findings. The original report already has content citing "Finding 1" through "Finding 10" but those were the original findings.

Hmm, this is a problem. The original report cites Finding 1, Finding 2, etc. And the new findings are also Finding 1-10. So there's ambiguity.

Let me look at the original report's citations:

• [Finding 1] — used for momentum dispersion, YTD gains, semiconductors, micro-cap decliners
• [Finding 2] — used for concentration, micro-cap YTD gainers, cross-market movers, short-covering
• [Finding 5] — Nuburu, NovaBay, VerifyMe
• [Finding 6] — Utilities, Corteva rebound
• [Finding 7] — past 30 day gainers, Russell 2000
• [Finding 8] — Ciena, Seagate daily movers
• [Finding 9] — Seagate daily losers
• [Finding 10] — VRAR, CTVA 7-day losers

And the new findings:

• Finding 1 — Stockanalysis past month gainers
• Finding 2 — Quant500 S&P 500 Oct 6
• Finding 3 — Business Insider market movers
• Finding 4 — Altindex bottom performers week
• Finding 5 — Yahoo Finance S&P 500 history
• Finding 6 — FRED
• Finding 7 — StockCharts.com
• Finding 8 — Investors.com
• Finding 9 — Dowjonestoday.net
• Finding 10 — tradewithmaya.com

So the new findings reuse the same numbers. This is confusing but I think the intent is that these are the updated finding numbers that should REPLACE or be integrated with the old ones. Actually, since the task says "Integrate the new findings into the existing report," and the new findings have their own Finding numbers, I think I should use the new Finding numbers for citations from those sources.

But wait — the original report's findings and the new findings have the same numbers but different sources. For example, the original Finding 1 was about momentum dispersion/YTD, and the new Finding 1 is about Stockanalysis past month gainers. These are actually somewhat related (both about gainers).

Hmm, this is genuinely ambiguous. Let me think about the most sensible interpretation.

I think the cleanest interpretation is: the "New findings from this round" are the findings gathered in THIS round of research. The original report was built from a PREVIOUS round. When integrating, I should cite the new findings using their new numbers (Finding 1-10 as given). But the original report already cites Finding 1-10 from the previous round.

Actually, I think the safest approach is to treat the new findings as a continuation/addition. But since they reuse numbers 1-10, there's a collision.

Let me reconsider. Perhaps the intent is that these new findings should be integrated, and I should use the finding numbers as given in the "New findings" section. The original report's citations might need to be reconciled.

Actually, you know what, I think the most reasonable approach given the ambiguity is to use the new Finding numbers (1-10) for the new sources, and where the original report cited findings that are now superseded or clarified by new findings, update accordingly. But I should preserve the original findings' content where it's still valid.

Hmm, but this creates a citation collision. Let me think differently.

Actually, I bet the intent is simpler than I'm making it. The "New findings" are the findings from this round. The report should be updated to incorporate them. The finding numbers in the "New findings" section (Finding 1-10) are the canonical numbers to use for those sources going forward. Where the old report cited a "Finding X" that corresponds to a new finding, I should use the new number. Where the old report cited a finding that's now part of a different number, I reconcile.

But there's no clean mapping. Let me just be pragmatic:

• For content that comes from the new findings, cite with the new Finding numbers.
• For content that was in the original report but isn't clearly from a new finding, I'll keep the original citations but... this is getting messy.

Let me take yet another approach. I'll assume the new findings REPLACE the old ones in terms of numbering, OR that they're meant to be integrated with the understanding that the numbers refer to the current round. Since the task says "Keep source URLs as inline citations where relevant," I'll make sure URLs are cited.

Actually, I think the cleanest and most defensible approach: Use the new Finding numbers (1-10) as given. For each piece of information, cite the appropriate new finding. Where the original report had information that's now supported by a new finding, use the new finding's number. Where information is genuinely new, cite the new finding.

But some original report content (like the micro-cap YTD gainers MGRT +1400%, the momentum z-scores ERAS +5.16) isn't clearly in the new findings. Let me check...

Original report content and its source:

• Momentum dispersion (ERAS +5.16, MU +5.16) — original Finding 1. Not in new findings. Hmm.
• Micro-cap YTD gainers (MGRT, ANL) — original Finding 2. Not in new findings.
• S&P 500 decliners (CTVA -79.49%, etc.) — original Finding 1. Not in new findings.

So there's content in the original report that doesn't map to new findings. This means the original report had findings that aren't in the new round.

OK here's my decision: I'll keep the original report's findings where they exist and are still valid, but I realize the numbering collision is a real issue. Let me look at whether the original report's findings and new findings might actually be the SAME sources re-cited.

Original report Finding 1: "Market structure shows a sharp style divergence..." — wait, that's actually the NEW Finding 1's content! Let me re-read.

Oh! I see. Let me re-read the original report's findings vs new findings.

The original report doesn't list its findings — it just cites them. The "New findings from this round" section lists Finding 1-10 with their content.

Wait, but the original report cites [Finding 1] for "Market structure shows a sharp style divergence over the past month: large-cap growth/tech led strongly (Nasdaq 100 +6.04%...)". And the NEW Finding 1 says EXACTLY that: "Market structure shows a sharp style divergence over the past month: large-cap growth/tech led strongly (Nasdaq 100 +6.04%, S&P 500 +1.96%) while value and small-caps lagged (Dow -2.11%, Russell 2000 -4.13%)..."

So the NEW Finding 1 is essentially the source for the original report's Finding 1 content! They're the same. Interesting.

Let me verify more:

• Original report Finding 2 content: concentration (NVDA ~$5.8T, etc.), micro-cap YTD gainers (MGRT, ANL), cross-market movers (MTEN, BIYA), short-covering (MUA, AVAT, TEVA).
• New Finding 2 content: Quant500 S&P 500 Oct 6 gainers/losers. This is about the daily session, NOT concentration or micro-cap gainers.

So New Finding 2 does NOT match original report Finding 2 content. The original report's Finding 2 content (concentration, MGRT, MTEN) comes from a different source not in the new round.

Hmm wait, but the original report Finding 2 citation is used for concentration data. And New Finding 2 is Quant500. These are different.

Let me check the original report's use of Finding 2:

• "the five largest names—NVDA (~$5.8T)... [Finding 2]"
• "Micro-cap/speculative names... MGRT... ANL... [Finding 2]"
• "Cross-market daily movers: MTEN (+83%) and BIYA (+71%)... [Finding 2]"
• "Short-covering signals. Short-interest decreases... MUA... AVAT... [Finding 2]"
• "Short-interest increases... TEVA... [Finding 2]"
• "Corteva... biggest single news loser (-83.8%) [Finding 2]"
• "Heartbeam (BEAT)... biggest news gainer (+50.5%) [Finding 2]"
• "UWMC led dividend yield at 33.33% [Finding 2]"

So original Finding 2 is a source with concentration data, micro-cap gainers, cross-market movers, short-interest data, and news. This is NOT Quant500. It's some other comprehensive source (maybe a market data aggregator).

New Finding 2 is Quant500 (S&P 500 daily movers Oct 6).

So these are genuinely different sources with the same number. This is a real collision.

Given this, I think the most sensible interpretation is:

The "New findings from this round" are the findings from THIS round. The original report was from a PREVIOUS round and had its own Finding 1-10. When I integrate, I should:

1. Preserve the original report's valid content.
2. Add the new findings' content.
3. Use the new Finding numbers for new findings.

But the collision means I can't cleanly distinguish.

Hmm, let me reconsider. Maybe the task intends for me to treat the new findings as the authoritative current findings, and the original report's citations should be updated to match. But since the original report's content doesn't all map to new findings, I need to keep some original citations.

Actually, I think I'm overcomplicating this. Let me take the pragmatic approach:

The new findings are numbered 1-10. I'll use these numbers for citing the new sources. For content in the original report that came from sources NOT in the new round (like the concentration data, micro-cap gainers, short-interest data), I'll... hmm, I don't have finding numbers for those.

Wait, actually, maybe I should reconsider whether the original report's findings ARE the new findings. Let me re-examine.

The original report says things like "[Finding 1]" for the momentum dispersion data. The new Finding 1 contains that exact data. So maybe the original report's Finding 1 = new Finding 1 (Stockanalysis). Let me check the URL.

The original report doesn't show URLs for its findings. But the new Finding 1 is Stockanalysis (stockanalysis.com/markets/gainers/month/). The original report's Finding 1 content matches Stockanalysis's past-month gainers. So YES, original Finding 1 = new Finding 1.

Let me check Finding 2 again. Original report Finding 2 content: concentration, MGRT/ANL micro-cap gainers, cross-market movers, short-interest, news. New Finding 2: Quant500 daily movers. These DON'T match.

But wait — maybe the original report's Finding 2 was a DIFFERENT source, and the new round renumbered or replaced it.

Hmm, let me look at what sources the original report's Finding 2 content might come from. Concentration data (NVDA $5.8T), micro-cap gainers (MGRT +1400%), cross-market movers (MTEN, BIYA), short-interest (MUA, AVAT, TEVA), news (Corteva -83.8%, Heartbeam +50.5%, UWMC 33.33%). This sounds like a comprehensive market screener/aggregator, possibly something like a specific data provider.

I don't have that source in the new round. So I can't cite it with a new number.

OK, I think the cleanest solution given the ambiguity: I'll keep the original report's finding citations as they are for content that doesn't map to new findings, and use the new finding numbers for new content. Where there's overlap, I'll reconcile.

But actually, this creates confusion for the reader. Let me think about what's most useful.

Actually, you know what? I think the intent of this exercise is that the "New findings" are additional research gathered, and I should integrate them into the report. The finding numbers in the new section (Finding 1-10) are what I should cite for those sources. The original report's findings that don't appear in the new round should retain their original citations (Finding 1, 2, etc. from the original round).

But the collision is unavoidable. Let me just make a decision and be consistent.

DECISION: I'll treat the new findings as the current round's findings (Finding 1-10 as given). For the original report's content that maps to a new finding, I'll cite the new finding. For the original report's content that does NOT map to any new finding (concentration data, MGRT/ANL, short-interest, cross-market movers, some news), I'll retain the original finding numbers but note that this creates a potential collision.

Hmm, actually, this is really problematic because the reader won't know which Finding 1 I mean.

Let me reconsider the whole thing. Maybe the simplest and most correct interpretation:

The original report and the new findings share the SAME finding numbers because they're meant to be the SAME findings, just with the new round providing updated/enhanced versions. So:

• Original Finding 1 = New Finding 1 (Stockanalysis) — same source, updated content
• Original Finding 2 = ???

No, that doesn't work either because Finding 2 content differs.

Let me try yet another interpretation: The new findings are a SEPARATE set, and I should integrate them. To avoid confusion, maybe I should just use the new finding numbers and drop/replace the old ones where they conflict, keeping old ones only where new ones don't cover.

Ugh, this is genuinely ambiguous. Let me just go with the most practical approach that produces a clean, useful report:

I'll use the new Finding numbers (1-10) for the new sources. For the original report's unique content (concentration, micro-cap gainers, short-interest, cross-market movers, some news), I'll keep those citations but I need numbers.

Actually, wait. Let me reconsider. Perhaps the original report's findings and the new findings are meant to be merged into a single set, and the numbering collision is intentional — meaning the new round's findings REPLACE the old round's findings with the same numbers where they overlap, and ADD new ones.

But there's no clean merge. Let me just look at the actual data overlap:

Original report content → which new finding covers it?

1. YTD gains (Russell 2000 +14.72%, Dow +7.03%) → New Finding 9 has Dow +7.19%, but not Russell 2000 YTD. Partial.
2. Style rotation (Nasdaq 100 +6.04%, etc.) → New Finding 1 covers this EXACTLY.
3. Concentration (NVDA $5.8T, etc.) → NOT covered by new findings. (New Finding 10 mentions NVDA largest holding but no market caps.)
4. Momentum dispersion (ERAS +5.16) → NOT covered.
5. Micro-cap YTD gainers (MU +231.48%, MGRT, ANL) → New Finding 1 mentions SVRN, PDSB, etc. but not MU +231.48% or MGRT/ANL. Partial.
6. S&P 500 decliners (CTVA -79.49%) → NOT covered.
7. Past 30 day gainers (Nuburu +2900%) → NOT covered by new findings.
8. 7-day losers (VRAR -86.5%) → New Finding 4 covers this EXACTLY.
9. Single-session movers (CIEN, STX) → New Findings 2, 3 cover this.
10. Utilities/energy bullish → New Findings 2, 3 cover.
11. Healthcare bearish → New Findings 2, 3 cover.
12. Short-covering (MUA, AVAT, TEVA) → NOT covered.
13. News (Corteva, Heartbeam, UWMC) → New Finding 2 has Corteva news? No, New Finding 2 is Quant500 daily movers. The news about Corteva -83.8% and Heartbeam isn't in new findings.

So there's substantial original content NOT covered by new findings. This means the original report had findings from a previous round that aren't in this round.

Given all this, I think the correct approach is:

The new findings are a NEW round (Finding 1-10 as labeled). The original report's findings were from a PREVIOUS round. To integrate cleanly, I should: